551,177

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087707 A1

(51) International Patent Classification[7]: C07D 487/04, A61K 31/519, A61P 35/00 // (C07D 487/04, 239:00, 321:00)

(21) International Application Number: PCT/GB2004/001214

(22) International Filing Date: 18 March 2004 (18.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 0307389.7 | 31 March 2003 (31.03.2003) | GB |
| 0312296.7 | 29 May 2003 (29.05.2003) | GB |
| 0319028.7 | 13 August 2003 (13.08.2003) | GB |
| 0325854.8 | 5 November 2003 (05.11.2003) | GB |

(71) Applicant *(for all designated States except US)*: **VERNALIS (CAMBRIDGE) LIMITED** [GB/GB]; Granta Park, Abington, Cambridge CB1 6GB (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PARRATT, Martin** [GB/GB]; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB). **BOWER, Justin, Fairfield** [GB/GB]; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB). **WILLIAMSON, Douglas** [GB/GB]; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB). **CANSFIELD, Andrew** [GB/GB]; Vernalis (Cambridge) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB).

(74) Agents: **HOWARD, Paul, Nicholas** et al.; Carpmaels & Ransford, 43-45 Bloomsbury Square, London WC1A 2RA (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*

*[Continued on next page]*

(54) Title: PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN MEDICINE




(I)

(57) Abstract: Compounds of formula (I) or salts, N-oxides, hydrates or solvates thereof are inhibitors of kinase activity, and useful for the treatment of, for example, cancer, psoriasis or restenosis: wherein ring A is an optionally substituted carbocyclic or heterocyclic radical. Alk represents an optionally substituted divalent Cl-$C_6$ alkylene radical. n is 0 or 1. Q represents a radical of formula $-(Alk^1)_p(X)_r-(Alk^2)_s-Z$ wherein in any compatible combination Z is hydrogen or an optionally substituted carbocyclic or heterocyclic ring; $Alk^1$ and $Alk^2$ are optionally substituted divalent $C_1$-$C_6$ alkylene radicals which may contain a -0-, -S- or -NR $^A$- link, wherein $R^A$ is hydrogen or $C_1$-$C_6$ alkyl; X represents -0-, -S-, -(C=O)-, -(C=S)-, $-SO_2-$, -SO-, -C(=O)O-, -OC(=O)-, -C(=O)$NR^A$-, -NR $^A$C(=O)-,-C(=S)$NR^A$-, -NR $^A$C(=S)-, - $SO_2NR^A$-, -NR $^A SO_2$-, -OC(=O)$NR^A$-, -NR $^A$C(=O)O-, or -$NR^A$- wherein $R^A$ is hydrogen or $C_1$-$C_6$ alkyl. p, r and s are independently 0 or 1. $R_1$ represents a radical $-(Alk^3)_a-(Y)b-(Alk^4)_d-B$ wherein a, b and d are independently 0 or 1; $Alk^3$ and $Alk^4$ are optionally substituted divalent C,-C3 alkylene radicals; Y represents a monocyclic divalent carbocyclic or heterocyclic radical having from 5 to 8 ring atoms, -0-, -S-, or -$NR^A$- wherein $R^A$ is hydrogen or $C_1$-$C_6$ alkyl; B represents hydrogen or halo, or an optionally substituted monocyclic carbocyclic or heterocyclic ring having from 5 to 8 ring atoms, or in the case where Y is -$NR^A$- and b is 1, then $R^A$ and the radical $-(Alk^4)_d$-B taken together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring. R represents hydrogen, halo, $C_1$-$C_6$ alkyl, Cl-$C_6$ alkoxy, $C_1$-$C_6$ alkylthio, phenyl, benzyl, cycloalkyl with 3 to 6 ring atoms, or a monocyclic heterocyclic group having 5 or 6 ring atoms.

WO 2004/087707 A1

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*